Gut bacteria are to blame for the failure of immune checkpoint therapy for ovarian cancer, new research reveals.

Over the past two decades, the idea of targeting transcription factors to combat malignancies has turned into a clinical reality.

Cullinan Oncology LLC (CGEM) stock has reached a new 52-week low, trading at $9.48 USD, signaling a period of significant ...

NEW YORK, NY, USA I 13, 2025 I Accropeutics Inc. (Accropeutics), a clinical-stage biotechnology company pioneering the development of novel ...

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

Cancer cells have special adaptation mechanisms that allow them to proliferate despite changes in their genetic makeup.

By targeting surface markers on cancer cells, engineered synthetic receptors expressed on immune cells can be directed to ...

Using a new technology and computational method, researchers from Fred Hutch Cancer Center and The University of Texas MD ...

In a pioneering collaboration with AbbVie, Northwestern researchers have discovered a new way to potentially treat cancer by ...

The Phase II eNRGy trial showed durable antitumor activity with zenocutuzumab (Bizengri) in patients with NRG1 ...

It is a useful therapy with several drawbacks that limit its effectiveness, including prolonged light sensitivity, poor tissue penetration and off-target toxicity. These drawbacks can prevent complete ...

Biologic medicines have transformed treatment for numerous chronic and life-threatening conditions such as cancer, ...